August 13, 2021 -- Mirus Bio announced an expansion of its TransIT VirusGen platform that is compliant with good manufacturing practices (GMP) viral vector manufacturing to support cell and gene therapy development, process activities, and commercial production.
The company said it has been creating transfection reagents for years and can now offer those products to biopharmaceutical manufacturers at the GMP level. The expansion, named TransIT VirusGen GMP transfection reagent, is designed to enhance the delivery of packaging and transfer vector DNA to suspension and adherent HEK 293 cell types to increase production of recombinant adeno-associated virus and lentivirus vectors, the company said.
Virus titers can be further optimized with Mirus' other enhancers in the product line. According to the company, the full product line helps minimize safety and regulatory risks by using GMP raw materials in upstream manufacturing processes.